North America antibiotics market is expected to grow by 2.3% annually in the forecast period and reach $14.67 billion by 2030 driven by rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic.
Highlighted with 26 tables and 56 figures, this 116-page report “North America Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:

  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Fiver Forces


The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country.

Based on Drug Class, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

  • Cephalosporin
  • Penicillin
  • Macrolides
  • Fluoroquinolones
  • Quinolones
  • Monobactam
  • Aminoglycosides
  • Carbapenem
  • Other Drug Classes



Based on Action Mechanism, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

  • Cell Wall Synthesis Inhibitors
  • Mycolic Acid Inhibitors
  • RNA Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • Other Mechanisms



Based on Drug Origin, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

  • Natural Antibiotics
  • Semi-synthetic Antibiotics
  • Synthetic Antibiotics



Based on Activity Spectrum, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

  • Broad-spectrum Antibiotics
  • Narrow-spectrum Antibiotics



Based on Route of Administration, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

  • Oral Administration
  • Intravenous Administration
  • Other Administration Routes



Based on Drug Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

  • Brand Antibiotics
  • Generic Antibiotics



Geographically, the following national/local markets are fully investigated:

  • U.S.
  • Canada
  • Mexico


For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)